WallStSmart
ELV

Elevance Health Inc

NYSE: ELV · HEALTHCARE · HEALTHCARE PLANS

$376.42
-0.06% today

Updated 2026-04-30

Market cap
$81.74B
P/E ratio
15.95
P/S ratio
0.41x
EPS (TTM)
$23.60
Dividend yield
1.82%
52W range
$269 – $415
Volume
2.0M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Elevance Health Inc (ELV) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$376.42
Consensus
$383.65
+1.92%
2030 Target
$13,466.15
+3477.43%
DCF
$1,012.43
+62.82% MoS
18 analysts:
11 Buy7 Hold0 Sell

Management guidance

Management has reiterated commitment to at least 12% adjusted EPS growth in 2027 following a significant senior leadership overhaul. No specific revenue targets were disclosed in available guidance, but the company is focused on resolving Medicare Advantage regulatory issues (CMS compliance deadline May 30, 2026) and executing a recovery strategy.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$22,453.66
$246.1B Rev × 20x P/S
Base case (2030)
$13,466.15
$246.1B Rev × 12x P/S
Bear case (2030)
$8,987.52
$246.1B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$171.3B$176.8B$199.1B$194.8B$205.4B$218.2B$231.8B$246.1B
Revenue growth—3.2%12.6%-2.2%5.4%6.2%6.3%6.2%
EPS$33.11$32.97$30.17$26.15$29.52$33.21$37.42$42.05
P/S ratio———12.0x12.0x12.0x12.0x12.0x
Implied price———$10,651.87$11,226.83$11,922.83$12,679.36$13,466.15

Catalysts & risks

Growth catalysts
+ CMS Medicare Advantage compliance deadline (May 30, 2026) - resolution critical to avoid enrollment sanctions
+ Q1 2026 earnings (April 22, 2026) - will reveal post-regulatory pressure business trajectory and member trends
+ 2027 Medicare Advantage payment rates finalized at 2.48% increase - supporting near-term reimbursement stability
+ Senior leadership restructuring execution - new management team tasked with improving Carelon profitability and core health benefits performance
+ Medicaid and Medicare Advantage membership stabilization - key to revenue growth recovery post-2026
Key risks
- Medicare Advantage regulatory headwinds - CMS sanctions could freeze new enrollment and suppress 2026-2027 revenue growth
- Medicaid membership decline - ongoing reductions in state Medicaid enrollment continue to pressure top-line
- Medical loss ratio compression - rising healthcare costs and prior underpricing in MA plans constraining margins
- Litigation exposure - active shareholder investigations into corporate governance and disclosure practices (pre-April 2024)
- Competitive pressures - UnitedHealth, Cigna, and Humana have stronger scale and brand positioning in MA segment

Methodology

Elevance Health Inc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 18 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.